Comparative Pharmacology
Head-to-head clinical analysis: THIOLA EC versus TIOPRONIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THIOLA EC versus TIOPRONIN.
THIOLA EC vs TIOPRONIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
THIOLA EC (tiopronin) is a reducing agent that breaks disulfide bonds in cystine, forming a mixed disulfide of tiopronin-cysteine, which is more soluble than cystine, thereby reducing cystine stone formation in the urine.
Tiopronin is a thiol compound that reduces cystine excretion by forming a soluble disulfide complex with cystine, thereby preventing cystine stone formation in patients with cystinuria. It also has antioxidant and anti-inflammatory properties, possibly through metal chelation and free radical scavenging.
Oral administration of 300 mg (1 capsule) three times daily, 1 hour before meals and at bedtime.
500-1000 mg orally three times daily for cystinuria; for rheumatoid arthritis: 250 mg orally four times daily, titrated up to 500 mg four times daily.
None Documented
None Documented
Terminal half-life: 6-12 hours in patients with normal renal function; may be prolonged in renal impairment (up to 30 hours in severe CKD)
Terminal elimination half-life is approximately 1.5-2 hours in adults with normal renal function. May be prolonged in renal impairment.
Renal: 80% as unchanged drug; biliary/fecal: <5%
Renal: ~80% as unchanged drug and metabolites, primarily via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<5%).
Category C
Category C
Cystine Depleting Agent
Cystine Depleting Agent